Title: Genomic and transcriptomic study of circulating tumor lymphocytes for the development of biomarkers associated with the response to treatment with inhibitors of the PD-L1 / PD1 pathway in patients with NSCLC
PI: Ángel Carracedo
Entidad de realización: IDIS
Funding: Fundación Ramón Areces
Start/End date: 2017 – 2020
Incorporation of immunotherapeutic drugs (nivolumab and pembrolizumab) in the treatment of lung cancer, has been an incredible advance allowing to increase the survival of patients. However, a high percentage of patients do not respond to these treatments, which represents a problem of therapeutic failure and health expenditure. For this reason, it is necessary to find and transfer to clinical practice biomarkers that help to identify the patients that can benefit from these treatments, as well as the biomarkers that allow the response to monitor and resistance during the duration of the same. With this aim, and from a translational point of view (with the joint collaboration of the Genomic Medicine Group and the Oncology Service of the University Hospital of Ourense), we propose to identify, validate and establish protocols to achieve the challenge of personalized medicine in the immunotherapeutic treatment of lung cancer. (1) Biopsy of the primary tumor by immunohistochemical analysis (PD-L1, and TILs), and genomic analysis of pure tumor cells, in order to describe biomarkers that help identify patients benefiting from immunotherapeutic treatment. (2) Peripheral blood, through the isolation of circulating tumor lymphocytes and their genomic characterization, in order to monitor the response during treatment.
Team: Ceres Fernandez Rozadilla, Olalla Maroñas Amigo, Ana Latorre Pellicer, Beatriz Sobrino Rey, Jesús García Mata, Karmele Areses Manrique, J. Luis Firvida Pérez, Carmen L. Doldán, María Carmen Penín Corderí
